Compare Quest Diagnostics Inc (DGX) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Match Group Inc — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Match Group Inc trades at $38.34 (market cap $8.94B). The key difference: Quest Diagnostics Inc is far larger — about 2.6× Match Group Inc's market cap, and Match Group Inc pays the higher dividend (2.09%). Which is the better fit depends on your goals.
| DGX | MTCH | |
|---|---|---|
Market Cap | $22.80B | $8.94B |
Sector | Health | Media |
52-Week High | $216.02 | $39.32 |
52-Week Low | $166.42 | $28.90 |
Enterprise Value | $28.82B | $11.89B |
Dividend Yield | 1.67% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
MTCH trades at $38.54, down 0.8% on the day, with a bullish technical signal from moving averages and strong analyst support (17 buy ratings, 0 sell). The company shows solid fundamentals with 4% revenue growth in Q1 2026, an 18.83% net income margin, and positive cash flow trends. Recent news highlights Tinder's turnaround progress and upcoming Q2 2026 earnings announcement on August 4, 2026.
The stock presents upside potential with a consensus price target of $41.63 (8% upside), supported by improving profitability and cash flow generation. Key risks include Tinder's user decline offset by price increases, high debt levels ($3.85B), and competitive pressures in the dating app space. The current valuation at 14.71 P/E appears reasonable given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
